Omnicell (OMCL) Earnings Date & Reports

Key Takeaways

• Omnicell reported third-quarter 2026 total revenue of $308 million, down 1% from $310.6 million a year earlier but above the high end of its own guidance range.
• Non-GAAP earnings per share (EPS) came in at $0.58, topping the roughly $0.42 consensus estimate by about 39% and up from $0.51 a year ago.
• GAAP net income reached $11.0 million, or $0.24 per diluted share, compared with $5.5 million, or $0.12 per share, in the prior-year quarter.
• Non-GAAP EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $45 million, exceeding the company's guidance range of $32 million to $37 million.
• Management raised its full-year 2026 non-GAAP EBITDA and EPS guidance while tightening revenue ranges, reflecting improved profitability and greater visibility.
• Shares moved higher after the results, although fourth-quarter revenue guidance came in below some analyst expectations.
• For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for Omnicell.
• To discover AI-driven trading ideas across the market, explore the Trending AI Robots page.

Earnings Context and Why It Matters

Omnicell is a healthcare technology provider focused on autonomous medication management, helping hospitals and health systems automate and connect the medication-use process. Its quarterly results offer investors a read on hospital capital spending, demand for connected device solutions, and the health of the company's recurring service and software revenue. After a strong first quarter, Omnicell has emphasized disciplined cost management and improving profitability, even as overall revenue growth has remained modest. The third quarter was closely watched for signs that demand for its next-generation Titan XT hardware and OmniSphere cloud platform is translating into bookings and a growing pipeline, while margins continue to benefit from favorable product and service mix.

Reported Results

For the third quarter ended September 30, 2026, Omnicell reported total revenue of $308 million, a 1% decline from $310.6 million in the same period last year. Product revenue was $173.1 million, down from $177.5 million, while service revenue rose to $134.8 million from $133.1 million. On a GAAP basis, net income was $11.0 million, or $0.24 per diluted share, compared with $5.5 million, or $0.12 per share, in the prior-year quarter.

On a non-GAAP basis, net income was $27 million, or $0.58 per diluted share, up from $24 million, or $0.51 per share, a year earlier. Non-GAAP EBITDA totaled $45 million, above the company's guidance range of $32 million to $37 million and up from $41 million in the third quarter of 2025. Revenue and profitability both exceeded the high end of management's previously provided guidance, while non-GAAP EPS comfortably surpassed the consensus estimate of roughly $0.42. Cash and cash equivalents stood at approximately $315 million at quarter-end, with operating cash flow of $33 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring healthcare technology names like Omnicell, the AI Screener offers a structured way to surface comparable opportunities and emerging patterns across the sector.

Market Reaction and Investor Sentiment

Omnicell's third-quarter report delivered a clear profitability beat, driven by disciplined cost management and favorable product and service mix. The market responded positively to the earnings strength, with shares rising modestly in the immediate aftermath of the announcement. However, sentiment was tempered by fourth-quarter revenue guidance, which implied a year-over-year decline and came in below some analyst projections. Investors appeared to weigh the company's improving margin profile and raised full-year profitability guidance against a still-soft top-line trajectory. The reaction suggests the market is rewarding Omnicell's execution and cost control while remaining cautious about near-term revenue growth as the company transitions toward its next-generation platform.

Forward Outlook and Key Factors to Monitor

Looking ahead, Omnicell provided fourth-quarter 2026 guidance of $295 million to $301 million in total revenue, non-GAAP EBITDA of $30 million to $36 million, and non-GAAP EPS of $0.41 to $0.49. For the full year, the company now expects total revenue of $1.225 billion to $1.231 billion, non-GAAP EBITDA of $187 million to $193 million, and non-GAAP EPS of $2.48 to $2.56. Management also tightened its annual recurring revenue (ARR) guidance to $660 million to $670 million and reiterated product bookings guidance of $425 million to $560 million.

Investors should monitor several factors in the coming quarters. First, the commercial ramp of Titan XT and OmniSphere will be important, as early shipments and customer adoption could signal the trajectory of future product revenue. Second, product bookings remain a key leading indicator, given the size and timing variability of hospital purchasing decisions.

Third, margin sustainability will be closely watched, as Omnicell's recent profitability gains have been supported by cost efficiency and customer mix. Finally, broader hospital capital spending trends and demand for medication automation solutions will continue to shape the top-line outlook. While profitability guidance has improved, revenue growth remains a central question for investors evaluating the company's longer-term opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations